PF-04455242
- Generic Name
- PF-04455242
Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release
Phase 1
Completed
- Conditions
- Bipolar Depression
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00988949
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00956956
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00939887
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00938301
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath